Status: Currently Official on 16-Feb-2025
Official Date: Official as of 01-May-2021
Document Type: USP Monographs
DocId: GUID-CEE865C8-04DE-43ED-A71F-1965FA341932_2_en-US
DOI: https://doi.org/10.31003/USPNF_M77004_02_01
DOI Ref: 7zh9q

Add the following:

▲Sodium Phenylbutyrate Tablets

DEFINITION
Sodium Phenylbutyrate Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of sodium phenylbutyrate ($C_{10}H_{11}NaO_2$).

IDENTIFICATION
- **A.** The UV spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.

ASSAY
- **Procedure**

Mobile phase: Methanol, water, and glacial acetic acid (49:50:1)

Diluent: Methanol and water (20:80)

Standard solution: 2.5 mg/mL of USP Sodium Phenylbutyrate RS in *Diluent*

Sample solution: Nominally 2.5 mg/mL of sodium phenylbutyrate prepared as follows. Finely powder NLT 10 Tablets and transfer a suitable portion equivalent to about 500 mg of sodium phenylbutyrate to a 200-mL volumetric flask, add about 140 mL of *Diluent*, and sonicate for 10 min with intermittent shaking. Dilute with *Diluent* to volume and mix well. Pass through a suitable filter of 0.45-µm pore size.

Chromatographic system
(See *Chromatography ⟨621⟩, System Suitability*.)

Mode: LC

Detector: UV 260 nm. For *Identification A*, use a diode array detector in the range of 200–400 nm.

Column: 4.6-mm × 15-cm; 5-µm packing L1

Flow rate: 1.2 mL/min

Injection volume: 20 µL

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of sodium phenylbutyrate ($C_{10}H_{11}NaO_2$) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of USP Sodium Phenylbutyrate RS in the *Standard solution* (mg/mL)

C_U = nominal concentration of sodium phenylbutyrate in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS
- **Dissolution ⟨711⟩**

Medium: Simulated intestinal fluid without enzyme; 900 mL

Apparatus 2: 75 rpm

Time: 30 min

Standard solution: (*L*/900) mg/mL of USP Sodium Phenylbutyrate RS in *Medium*, where *L* is the label claim in mg/Tablet. Sonicate, if necessary, to dissolve.

Sample solution: Pass a portion of the solution under test through a suitable filter of 0.45-µm pore size.

Instrumental conditions

Mode: UV

Analytical wavelength: 260 nm

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of sodium phenylbutyrate ($C_{10}H_{11}NaO_2$) dissolved:

$$\text{Result} = (A_U/A_S) \times (C_S/L) \times V \times 100$$

A_U = absorbance of the *Sample solution*

A_S = absorbance of the *Standard solution*

C_S = concentration of USP Sodium Phenylbutyrate RS in the *Standard solution* (mg/mL)

L = label claim (mg/Tablet)

V = volume of *Medium*, 900 mL

Tolerances: NLT 85% (*Q*) of the labeled amount of sodium phenylbutyrate ($C_{10}H_{11}NaO_2$) is dissolved.

• **Uniformity of Dosage Units ⟨905⟩:** Meet the requirements

IMPURITIES

• **Organic Impurities**

Mobile phase: Methanol, water, and glacial acetic acid (44:55:1)

Diluent: Methanol and water (20:80)

System suitability stock solution A: 0.08 mg/mL of USP Phenylbutyrate Related Compound A RS in *Diluent*. Sonicate to dissolve, if necessary.

System suitability stock solution B: 0.06 mg/mL of USP Phenylbutyrate Related Compound B RS in *Diluent*. Sonicate to dissolve, if necessary.

System suitability solution: 4 mg/mL of USP Sodium Phenylbutyrate RS, 0.008 mg/mL of USP Phenylbutyrate Related Compound A RS, and 0.006 mg/mL of USP Phenylbutyrate Related Compound B RS prepared as follows. Dissolve a suitable amount of USP Sodium Phenylbutyrate RS with 50% of the total flask volume of methanol and sonicate, if necessary, to dissolve. Add suitable volumes of *System suitability stock solution A* and *System suitability stock solution B* to the same flask and dilute with *Diluent* to volume.

Sensitivity solution: 1.5 µg/mL each of USP Phenylbutyrate Related Compound A RS and USP Phenylbutyrate Related Compound B RS from *System suitability stock solution A* and *System suitability stock solution B* in *Diluent*

Standard solution: 0.008 mg/mL of USP Phenylbutyrate Related Compound A RS and 0.006 mg/mL of USP Phenylbutyrate Related Compound B RS from *System suitability stock solution A* and *System suitability stock solution B* in *Diluent*

Sample solution: Nominally 4 mg/mL of sodium phenylbutyrate in *Diluent* prepared as follows. Transfer a suitable quantity from NLT 20 powdered Tablets, equivalent to about 200 mg of sodium phenylbutyrate, to a 50-mL volumetric flask. Add about 35 mL of *Diluent* and sonicate with intermittent shaking. Dilute with *Diluent* to volume. Pass through a suitable filter of 0.45-µm pore size.

Chromatographic system

(See *Chromatography ⟨621⟩, System Suitability*.)

Mode: LC

Detector: UV 245 nm

Column: 2.1-mm × 10-cm; 1.7-µm packing L1

Column temperature: 35°

Flow rate: 0.2 mL/min

Injection volume: 2 µL

System suitability

Samples: *System suitability solution*, *Sensitivity solution*, and *Standard solution*

Suitability requirements

Resolution: NLT 6.0 between the phenylbutyrate related compound B and phenylbutyrate peaks, *System suitability solution*

Relative standard deviation: NMT 5.0% for the phenylbutyrate related compound A and phenylbutyrate related compound B peaks, *Standard solution*

Signal-to-noise ratio: NLT 10 for the phenylbutyrate related compound A and phenylbutyrate related compound B peaks, *Sensitivity solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of phenylbutyrate related compound A or phenylbutyrate related compound B in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of phenylbutyrate related compound A or phenylbutyrate related compound B from the *Sample solution*

r_S = peak response of phenylbutyrate related compound A or phenylbutyrate related compound B from the *Standard solution*

C_S = concentration of USP Phenylbutyrate Related Compound A RS or USP Phenylbutyrate Related Compound B RS in the *Standard solution* (mg/mL)

C_U = nominal concentration of sodium phenylbutyrate in the *Sample solution* (mg/mL)

Calculate the percentage of any individual unspecified impurity in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of any individual unspecified impurity from the *Sample solution*

r_S = peak response of phenylbutyrate related compound A from the *Standard solution*

C_S = concentration of USP Phenylbutyrate Related Compound A RS in the *Standard solution* (mg/mL)

C_U = nominal concentration of sodium phenylbutyrate in the *Sample solution* (mg/mL)

Acceptance criteria: See *Table 1*. The reporting threshold is 0.05%, except for phenylbutyrate related compound B.

Table 1

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Phenylbutyrate related compound A	0.30	0.10
Phenylbutyrate related compound B	0.68	0.05
Sodium phenylbutyrate	1.0	—
Any individual unspecified impurity	—	0.10
Total impurities	—	0.5

ADDITIONAL REQUIREMENTS

• **Packaging and Storage:** Preserve in tight containers. Store at controlled room temperature.

• **USP Reference Standards** ⟨11⟩

USP Sodium Phenylbutyrate RS

USP Phenylbutyrate Related Compound A RS

3-Benzoylpropionic acid;
4-Oxo-4-phenylbutanoic acid.
$C_{10}H_{10}O_3$ 178.18

USP Phenylbutyrate Related Compound B RS

α-Tetralone;
3,4-Dihydronaphthalen-1(2*H*)-one.
$C_{10}H_{10}O$ 146.19▲ (USP 1-May-2021)

Auxiliary Information - Please check for your question in the FAQs before contacting USP.

Topic/Question	Contact	Expert Committee
SODIUM PHENYLBUTYRATE TABLETS	Documentary Standards Support	SM32020 Small Molecules 3
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM32020 Small Molecules 3

Chromatographic Database Information: Chromatographic Database

Most Recently Appeared In:
Pharmacopeial Forum: Volume No. PF 44(2)

Current DocID: GUID-CEE865C8-04DE-43ED-A71F-1965FA341932_2_en-US

DOI: https://doi.org/10.31003/USPNF_M77004_02_01

DOI ref: 7zh9q